CHEO.Y Stock Overview
Provides implantable hearing solutions for children and adults worldwide. More details
| Snowflake Score | |
|---|---|
| Valuation | 1/6 |
| Future Growth | 2/6 |
| Past Performance | 4/6 |
| Financial Health | 6/6 |
| Dividends | 3/6 |
Cochlear Limited Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | AU$97.60 |
| 52 Week High | AU$115.85 |
| 52 Week Low | AU$85.33 |
| Beta | 0.46 |
| 11 Month Change | 3.00% |
| 3 Month Change | -4.14% |
| 1 Year Change | 13.42% |
| 33 Year Change | 18.88% |
| 5 Year Change | 27.67% |
| Change since IPO | 217.40% |
Recent News & Updates
Recent updates
Shareholder Returns
| CHEO.Y | US Medical Equipment | US Market | |
|---|---|---|---|
| 7D | 2.3% | 1.5% | 2.2% |
| 1Y | 13.4% | 20.8% | 31.6% |
Return vs Industry: CHEO.Y underperformed the US Medical Equipment industry which returned 20.9% over the past year.
Return vs Market: CHEO.Y underperformed the US Market which returned 31.7% over the past year.
Price Volatility
| CHEO.Y volatility | |
|---|---|
| CHEO.Y Average Weekly Movement | 3.4% |
| Medical Equipment Industry Average Movement | 8.1% |
| Market Average Movement | 6.3% |
| 10% most volatile stocks in US Market | 15.7% |
| 10% least volatile stocks in US Market | 3.1% |
Stable Share Price: CHEO.Y has not had significant price volatility in the past 3 months compared to the US market.
Volatility Over Time: CHEO.Y's weekly volatility (3%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1981 | 5,047 | Dig Howitt | www.cochlear.com |
Cochlear Limited provides implantable hearing solutions for children and adults worldwide. It offers cochlear implant systems, sound processor upgrades, bone conduction systems, accessories, and other products. The company was founded in 1981 and is headquartered in Sydney, Australia.
Cochlear Limited Fundamentals Summary
| CHEO.Y fundamental statistics | |
|---|---|
| Market cap | US$12.68b |
| Earnings (TTM) | US$231.87m |
| Revenue (TTM) | US$1.45b |
54.7x
P/E Ratio8.7x
P/S RatioIs CHEO.Y overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| CHEO.Y income statement (TTM) | |
|---|---|
| Revenue | AU$2.24b |
| Cost of Revenue | AU$562.10m |
| Gross Profit | AU$1.67b |
| Other Expenses | AU$1.32b |
| Earnings | AU$356.80m |
Last Reported Earnings
Jun 30, 2024
Next Earnings Date
Feb 13, 2025
| Earnings per share (EPS) | 5.45 |
| Gross Margin | 74.86% |
| Net Profit Margin | 15.96% |
| Debt/Equity Ratio | 0% |
How did CHEO.Y perform over the long term?
See historical performance and comparison